Effect of Presenilin Mutations on APP Cleavage; Insights into the Pathogenesis of FAD

Nuomin Li, Kefu Liu, Yunjie Qiu, Zehui Ren, Rongji Dai, Yulin Deng and Hong Qing*

School of Life Science, Beijing Institute of Technology, Beijing, China

Alzheimer disease (AD) is characterized by progressive memory loss, reduction in cognitive functions, and damage to the brain. The β-amyloid precursor protein can be sequentially cleaved by β-secretase and γ-secretase. Mutations in the presenilin1 (PS1) are the most common cause of Familial Alzheimer’s disease (FAD). PS1 mutations can alter the activity of γ-secretase on the cleavage of the β-amyloid precursor protein, causing increased Aβ production. Previous studies show that the β-APP-C-terminal fragment is first cleaved by β-secretase, primarily generating long fragments of Aβ48 and Aβ49, followed by the stepwise cleavage of every three amino acid residues at the C terminus, resulting in Aβ48–45, Aβ45–42 line and Aβ49–46, Aβ46–43, Aβ43–40 line. Here, we used LC-MS/MS to analyze unique peptides IAT, VVIA, ITL, TVI, IVI through sequential cleavage, combined with ELISA to test the level of Aβ42 and Aβ40 for validation. The results show that most FAD mutant PS1 can alter the level of Aβ42 and Aβ40 monitored by the Aβ42/Aβ40 ratio. Among them, six mutants (I143T, H163P, S170F, Q223R, M233V, and G384A) affect the Aβ42/40 ratio through both Aβ49–40 and Aβ48–38 lines; L166P through decreasing the Aβ49–40 line, six mutants (I143V, M146V, G217A, E280A, L381V, and L392V) through increasing the Aβ48–42 line. More importantly, we found some mutations can affect the γ-secretase cleavage preference of α-CTF and β-CTF.

In conclusion, we found that the FAD PS1 mutations mainly increase the generation of Aβ42 by decreasing the cleavage of Aβ42–Aβ38 and Aβ43–Aβ40.

Keywords: Familial Alzheimer’s disease, γ-secretase, presenilin1, amyloid β-peptide

INTRODUCTION

Alzheimer disease (AD) is the most common neurodegenerative disease. One of the main etiological hallmarks of AD is excessive production of Aβ (Bentahir et al., 2006; Cacquevel et al., 2012). Aβ peptides aggregate and deposit into soluble oligomers, fibrils, and senile plaques, which are closely associated with synaptic dysfunction and neuronal network perturbations, finally causing gross atrophy of the brain (Lesne et al., 2006; Shankar et al., 2008; Sun et al., 2015). Aβ is a 38–43 amino acid peptide derived from the β-APP through sequential cleavage by β-secretase (BACE1) and γ-secretase (Adlard et al., 2008; Thinakaran and Koo, 2008; Barnwell et al., 2014). BACE1 is an aspartyl protease β-site APP cleaving enzyme1 that cleaves APP mainly at a unique site, whereas the γ-secretase complex cleaves the CTF at several sites.
with preference for positions 40 and 42, forming the Aβ1−40 and Aβ1−42 peptides (Jonsson et al., 2012). Previous studies indicated that compared to other forms, such as Aβ1−4, Aβ1−38, Aβ1−42, and Aβ3−40 are more amyloidogenic (Chow et al., 2010). In particular, Aβ42, which is more prone to aggregate and form soluble oligomers that eventually form insoluble plates, is more amyloidogenic (Kakuda et al., 2006; Czirr et al., 2008). Clinical studies indicated that Aβ1−42 peptide showed a higher percentage concentration in AD patients (Burdick et al., 1992; Kim et al., 2007). In the physiological condition, more than 90% of Aβ1 is a shorter form of Aβ40 and less than 5% of Aβ is a longer form of Aβ42 (Sun et al., 2015).

Autosomal dominant FAD is a rare form of AD and usually presents before the age of 65 years in individuals with a positive family history in at least three generations (Wu et al., 2012). Currently, more than 185 mutations have been identified in PS1, 13 in presenilin 2 (PS2) and 33 in APP among FDA patients (Cacquevel et al., 2012). PS1 is a trans-membrane protein that is an important component of the catalytic core of γ-secretase (Fernandez et al., 2014). γ-secretase, which is a multiprotein complex, is an unusual intramembranous cleaving aspartyl protease composed of presenilin, Nicastrin, Pen-2 and Aph-1 (Yu et al., 2000; Francis et al., 2002; Goutte et al., 2002; Christensen et al., 2004). PS1 is a highly conservative membrane protein, with nine TMDs. Large numbers of pathogenic mutations have been found throughout the coding sequence of PS1. Most of the PS1 mutations in FAD are located at TMDs (Wanngren et al., 2004). PS1 is a highly conservative membrane protein, with nine TMDs. Large numbers of pathogenic mutations have been found throughout the coding sequence of PS1. Most of the PS1 mutations in FAD are located at TMDs (Wanngren et al., 2004). PS1 is a highly conservative membrane protein, with nine TMDs. Large numbers of pathogenic mutations have been found throughout the coding sequence of PS1. Most of the PS1 mutations in FAD are located at TMDs (Wanngren et al., 2004).

A study of the PS mutations in FAD indicated that more than 90% of Aβ1 is a shorter form of Aβ40 and less than 5% of Aβ is a longer form of Aβ42 (Sun et al., 2015). This is important in understanding the underlying mechanism of PS mutations during the onset of AD.

### MATERIALS AND METHODS

**DNA Constructs and Mutagenesis**

BACE1-myc-his, pcC99, pcC83, wild-type PS1 human cDNAs (PS1-WT) were obtained from Weihong Song lab (University of British Columbia, Vancouver, BC, Canada). Mutations in PSEN1, (namely, I143T, I143V, M146V, H163P, L166P, S170F, G217A, M233V, Q223R, E280A, L381V, G384A, D385A, and L392V) were generated by overlap extension PCR on the plasmid pcDNA4.1/PS1-WT using corresponding primers (Supplementary Table S1). The PCR fragments were then digested using EcoRI/HindIII, and subcloned into pcDNA4.1.

**Cell Culture and Transfection**

Human embryonic kidney 293 (HEK 293) cells, stably expressing “Swedish” mtAPP695 and BACE1 (2EB2 cell line), were cultured in Dulbecco’s Modified Eagle Media, which is a Nutrient Mixture F-12 (GIBCO, CA) supplemented with 10% fetal bovine serum (FBS; Gibco) and 1% penicillin/streptomycin (Gibco). Stable cell lines were selected using 200 mug/ml Zeocin and G418 (Invitrogen). Human embryonic kidney 293 (HEK 293) cells were cultured in Dulbecco’s Modified Eagle Media (GIBCO, CA) supplemented with 10% FBS (GIBCO) and 1% penicillin/streptomycin (Gibco). The cDNA constructs were transiently transfected into the cells using the Lipofectamine 2000 reagent (Invitrogen), according to the manufacturer’s instructions.
**Extraction of Tri-, Tetra-, and Pentapeptides from Living Cultured Cells**

2EB2 cells were transfected with PS1 or PS1 with various mutations. HEK293 cells co-transfected with pcC99 or pcC83 and PS1 or PS1 with various mutations were cultured to confluence in 10 cm dishes. Protease inhibitors (Protease inhibitor Cocktail Tablets, Roche, 0469312001) and 1 mM 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF, sigma, A8456) were added into the conditioned medium 44 h after transfection. The cells were washed rapidly with ice-cold PBS, and then, immediately boiled for 2 min. The boiled samples were sonicated for 3 min and centrifuged. The supernatant was then concentrated using a speed vacuum concentrator, and finally, subjected to an LC-MS/MS analysis of the tripeptide and tetrapeptide (Okochi et al., 2013).

**Aβ ELISA**

The conditioned medium was collected for an Aβ (Aβ40 and Aβ42, Invitrogen) level assay. Protease inhibitor and 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride were added to the conditioned medium 4 h before collection to prevent degradation of Aβ. The levels of Aβ species (Aβ40 and Aβ42) were measured by ELISA Kits according to the manufacturer’s instructions.

**Identification and Quantification of Cleavage Peptides by LC-MS/MS**

An electrospray ionization tandem quadruple mass spectrometer, (Agilent 6460, USA) was used by ultra-performance liquid chromatography (Agilent 1260), was used to identify and quantify the cleavage peptides. Samples were maintained at 4°C in the auto sampler. To quantify each peptide, a combination of precursor ion product ion pair was monitored using multiple reaction monitoring (MRM) modes. MRM methods were measured by LC-MS/MS as described previously (Takami et al., 2009). The m/z values for these peptides were as follows: 502.7 and 199.2 for VIVAT; 425.7 and 261.2 for FLF; 345.8 and 215.1 for I1; 329.8 and 185.2 for VIV; 303.7 and 185 for IAT; 331.8 and 185.1 for VIT; 331.8 and 173.1 for TVI; 401.2 and 171.1 for VVIA.

**Immunoblotting**

Cells were lysed 48 h after transfection in a RIPA Lysis Buffer with 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.1% SDS, Protease Inhibitor cocktail (Roche) and AEBSF. Sonication was done using an Ultrasonic Cell Disruptor (Sonics). The lysates were centrifuged at 14,000 rpm for 2 min. The boiled samples were sonicated for 3 min and centrifuged. The supernatant was then concentrated using a speed vacuum concentrator, and finally, subjected to an LC-MS/MS analysis of the tripeptide and tetrapeptide (Okochi et al., 2013).

**Statistical Analysis**

Quantifications were done from data generated during three independent experiments. Values represent mean ± standard error of the mean. Comparisons of more than two groups were carried out using one-way ANOVA and Dunnett’s post hoc test using PS1 WT values as the control group (Fernandez et al., 2014). Statistical significance between the two groups was determined by an unpaired two-tailed t-test. P < 0.05 was considered to be statistically significant.

**RESULTS**

**Human FAD PS1 Mutations Increase the Production of CTF**

In order to better understand the mechanisms of FAD PS1 mutations, 14 different PS1 mutations were selected and transiently transfected into 2EB2 cells that stably overexpressed Swedish APP and BACE1 (Qing et al., 2004). PS1 has nine TMDs and harbors the catalytic site with two conserved aspartate residues located in TMD6 and TMD7 (Wolfe et al., 1999; Henricson et al., 2005; Spasic et al., 2006). It was reported that most PS1 mutations are located in TMD2, TMD3, TMD4, TMD5, TMD6, and TMD7. Among them, TMD1-6 and TMD8-9 are hydrophobic. TMD7 has a partial hydrophilic catalytic cavity and is very sensitive to mutations, which dramatically reduce its capability to insert into the cell membrane (Wanngren et al., 2014). TMD7 is part of the hydrophilic catalytic cavity, which is inserted in the hydrophobic core of the membrane, and probably protected by stable hydrophobic domains that include TMD1-6 and TMD8-9. TMD6 is also susceptible to changes in amino acid residues. Fourteen different FAD PS1 mutations that we selected are located in TMDs. Four are located in TMD2 (I143T/V, M146V, H163P); one in TMD3 (L166P, S170F); one in TMD4 (G217A), two in TMD5 (Q223R, M233V); one in H7 (E280A); and, three in TMD7 (L381V, L392V, G384A). One mutant (D385A) was also used as a negative control (Uttner et al., 2010). Except for L381V and G384A that have been well-studied, the rest have rarely, if ever, been studied. Vector alone, PS1 WT (wild type) or PS1 mutants, were transiently transfected into 2EB2 cells. Forty-eight hours after transfection, cells were collected, lysed, and a Western Blot was used to analyze the expression level of APP and CTFs, especially CTF99 expression. The levels of PS1 expression were used to verify the transfection efficiency. Compared with the vector alone (pcDNA4.1), both WT PS1 and PS1 with mutations could be transfected with high efficiency into the 2EB2 cell line. While the negative control mutation (D385A) did not affect the level of APP CTF expression, others, especially I143T, S170F, M233V, and L392V, increased the expression of APP CTF (Figures 1A–C).
Li et al. Cleaved Aβ Forms in Presenilin1 Mutants

FIGURE 1 | Familial Alzheimer’s disease PS1 mutations affect CTF level. Expression levels of APP, CTF in 2EB2 cells expressing empty vector, PS1 WT, I143T, I143V, M146V, H163P, L166P, S170F, G217A, Q223R, M233V, E280A, L381V, G384A, D385A, L392V. (A) Cell lysates from human Swedish mutant APP695 and BACE1 double expression stable cell line 2EB2 were analyzed by Western Blot. APP, APP CTFs were detected with the C20 polyclonal antibody, PS1-NT was detected with the rat anti-presenilin-1 monoclonal antibody (Millipore, MAB1563). (B) Quantification of APP in 2EB2 cells in (A). (C) Quantification of C99 in 2EB2 cells in (A). *P < 0.05; **P < 0.01.

FIGURE 2 | Effects of PS1 WT and PS1 Mutants on long Aβ Cleavage in 2EB2 cell line by ELISA (A,B). Conditioned medium from 2EB2 cells expressing empty vector, PS1 WT or FAD PS1 mutants were analyzed for levels of secreted Aβ40 and Aβ42 using ELISA kit. (A) The levels of Aβ40 and Aβ42 are plotted in relative to PS1 WT. (B) The Aβ42/Aβ40 ratio. *P < 0.05; **P < 0.01.

Human FAD PS1 Mutations Influence APP Cleavage Process

To investigate the effect of human FAD PS1 on the APP cleavage process, empty vector (pcDNA4.1), PS1 WT or PS1 mutants were again transiently transfected into 2EB2 cells. Forty-eight hours after transfection, both the conditional medium and the cells were collected. ELISA was used to measure the levels of Aβ42 and Aβ40 in the conditional medium. Cells were lysed and the small peptides (tripetide and tetrapeptide) were measured using LC-MS/MS (Agilent 6460, USA). ELISA results showed that compared to PS1 WT, the dominant negative mutation (D385A) did not affect the expression levels of Aβ42 and Aβ40, while most FAD PS1 mutants showed an increased Aβ42/Aβ40 ratio through different lines. For example, L166P increased the ratio of Aβ42/Aβ40 by lowering the level of Aβ40. I143V, M146V, G217A, E280A, L381V, and L392V increased the Aβ42/Aβ40 ratio through increased expression of Aβ42. The rest of the mutations increased the ratio of Aβ42/Aβ40 through both decreasing Aβ40
and increasing Aβ42 levels at the same time (Figures 2A, B). The amounts of tripeptide and tetrapeptide produced during the stepwise processing of longer form Aβ in living cells were then measured (Figures 3 and 4). The result indicated that neither the negative control nor any of the selected FAD PS1 mutations affected the selectivity of the γ-secretase cleavage of long form Aβ, judged by the total level of Aβ49-40 relative to that of total Aβ-related small peptides (Figure 4A). Compared to the PS1-WT, except for L166P and D385A mutations, most PS1 mutations were able to reduce the relative rate of Aβ42 cleavage into Aβ38. This reduction was concluded based upon the level of VVIA relative to that of total Aβ48-42 related small peptides (Figure 4B). Correspondingly, compared with PS1-WT, most FAD PS1 mutations (I143T, H163P, L166P, S170F, Q223R, M233V, E280A, and G384A) were able to decrease the relative rate of Aβ43 cleavage into Aβ40. This finding is based upon the level of IAT relative to that of the total Aβ49-40 related small peptides (Figure 4C). The LC-MS/MS results are consistent with the results from ELISA and Western Blot.

---

**FIGURE 3** | Detection of related small peptide species of Aβ. (A) The chromatography of IAT standard peptides. (B) The intensity of multiple reactions monitoring (MRM) ion chromatography of ITA. (1) Its transition is m/z = 303.7/185. Black, pCDNA4.1; Red, PS1; Blue, M233V. (C) The chromatography of VVIA standard peptides. (D) The intensity of multiple reactions monitoring (MRM) ion chromatography of VVIA. (2) Its transition is m/z = 401.2/171.1. Black, pCDNA4.1; Red, PS1; Blue, M233V. (E) Aβ species in lysates of 2EB2 cells in a 10 cm dish overexpressing PS1 WT.
Li et al. Cleaved Aβ Forms in Presenilin1 Mutants

FIGURE 4 | Effects of PS-WT1 and PS1 Mutants on long Aβ Cleavage in 2EB2 cell line by LC-MS/MS. (A) Fold changes of the relative rate of Aβ49-40/total Aβ production. (B) Fold changes of the relative VVIA levels in cell lysates of 2EB2 cell line. (C) Fold changes of the relative IAT levels in cell lysates of 2EB2 cells line. (D)Fold changes of the relative VIT, TVI, and VVIA levels in cell line expressing PS1 and PS1 FAD mutants. (E) Fold changes of the relative ITL, VIV, and IAT levels in cell line expressing PS1 and PS1 FAD mutants. *P < 0.05; **P < 0.01.

Human FAD PS1 Mutations Differ in Their Effect on Aβ Generated by β-CTF Line

Amyloid precursor protein can be cleaved into α-CTF (CTF83) and β-CTF (CTF99) by α-secretase and β-secretase in vivo, respectively. Therefore, we want to examine whether CTF83 can affect the CTF99 cleavage with PS1 mutations. pzC99, which is the cDNA encoding CTF99, was inserted into the pcDNA4.1 vector. We co-transfected transiently pzC99 with the empty vector, PS1 WT or PS1 mutants, into HEK293 cells. Forty-eight hours after transfection, both the condition medium and the cells were collected. The levels of Aβ42 and Aβ40 in the culture medium were similar to the previous ELISA results (Figures 2A,B). Most FAD PS1 mutations also increased the ratio of Aβ42/Aβ40 as shown before: L166P increased the ratio of Aβ42/Aβ40 by reducing Aβ40 level; I143V, M146V, G217A, E280A, L381V, and G384 increased the ratio of Aβ42/Aβ40 by increasing Aβ42 level; and finally, the rest of the mutations increased the ratio of Aβ42/Aβ40 by both reducing Aβ40 and increasing Aβ42 levels (Figures 5A,B). Cells were then lysed and the tripeptide and tetrapeptide were measured using LC-MS/MS (Figure 3). Compared with PS1-WT, some FAD PS1 mutations (I143T, I143V, M146V, H163P, S170F, G217A, Q223R, M233V, E280A, L381V, G384A, and L392V), showed elevated levels of Aβ42 as a result of lower VVIA, which was produced by the cleavage of Aβ42 into Aβ38, L166P and
negative control had no effect on the VVIA level (Figure 5C). The results of Aβ49–Aβ40 line were slightly different (Figure 4E).

Some FAD PS1 mutations (I143T, M146V, H163F, R170F, Q223R, M233V, E280A, L381V, and L392V) secreted lower levels of Aβ40, causing a lower level of IAT to be generated by the cleavage of Aβ43 into Aβ40. Others, such as I143V, G217A, and G384A, as well as the negative control, did not affect the IAT levels (Figure 5D). Among them, M146V, G384A, L381V, and L392V showed slightly different results from the previous data (Figures 4B,C). This could be due to CTF83 competing with CTF99 for cleavage by γ-secretase.

Human FAD PS1 Mutations Differ in Their Effect on Aβ by α-CTF Line

The above results showed that FAD PS1 mutations differ in their effects on the Aβ generation line of APP and CTF99, especially in the Aβ49–Aβ40 line. APP could be cleaved by different secretase to generate α-CTF and β-CTF. Subsequently, they could be sequentially cleaved to produce Aβ fragments using γ-secretase. Both α-CTF and β-CTF can give rise to the tri- and tetra-peptides, but only β-CTF can eventually generate Aβ42. Thus, we further tested the hypothesis that the presence of CTF83 may affect the cleavage of CTF99.
FIGURE 6 | Effects of PS1-WT and PS1 Mutants on CTF83 Cleavage. (A) Fold changes of the relative VVIA levels in cell lysates of HEK293 transfected pzC83 and PS1-WT or FAD PS1 mutations. (B) Fold changes of the relative IAT levels in cell lysates of HEK293 transfected pzC83 and PS1-WT or FAD PS1 mutations. ∗P < 0.05; **P < 0.01.

FIGURE 7 | Summarize the effects on specific peptides cleaved from long Aβ in different mutations. The APP can be sequential cleavage by β-secretase (BACE1)/α-secretase and γ-secretase. APP-C-terminal fragment is cleaved at the ε-site by γ-secretase, generating primarily long fragments, Aβ48 and Aβ49, followed by stepwise cleavage of every three amino acid residues at the C terminus, generating unique peptide. PS1 negative control, D385A, showed no change in unique peptide VVIA and IAT. Six mutations (I143T, H163P, S170F, Q223R, M233V, and G384A) change the ratio of Aβ42/40 by decreasing the cleavage of Aβ43-40 and Aβ42-38. L166P affect the ratio of Aβ42/40 by decreasing the cleavage of Aβ43-40. Six mutations (I143V, M146V, G217A, E280A, L381V, and L392V) affect the ratio of Aβ42/40 by decreasing the cleavage of Aβ42-38.

ELISA results showed that Aβ42 could not be detected in either PS1-WT or FAD PS1 mutations. The LC-MS/MS results showed that compared to PS-WT, some FAD PS1 mutations (I143T, I143V, H163P, S170F, L381V, and L392V) produced lower levels of VVIA (Figure 6A). Meanwhile, others (I143T, H163P, S170F, G217A, M233V, and G384A) produced lower levels of IAT (Figure 6B). Combined with the data of a specific peptide IAT cleaved from APP and a β-CTF cleavage using γ-secretase (Figures 4 and 5), we propose that the existence of α-CTF may affect the β-CTF cleavage in certain, (i.e., M146V,
The PS1 mutation is known to be a key heredity factor of FAD. Mutation in PS1 can cause changes to $\gamma$-secretase activities, resulting in the alteration of the $\alpha$-42/40 ratio. Recent research data show that $\beta$-APP can be generated by a series and continuous cleavage using $\gamma$-secretase (Takami et al., 2009; Okochi et al., 2013; Olsson et al., 2014). LC-MS/MS can be used to monitor the cleavage progress by following the tripeptides and tetrapeptides generated during the process. Based on the $\alpha$-48–$\alpha$-38 and $\alpha$-49–$\alpha$-40 cleavage lines, 14 PS1 mutations impacting the $\alpha$-42/40 ratio via different lines of $\alpha$-generated line were reported. Here, we discovered four significant findings. First, the PS1 negative control (D385A) showed no change in $\alpha$-42, $\alpha$-40 level, or $\alpha$-42/40 ratio. This outcome is likely because they do not affect the cleavage of CTF83 and CTF99, especially the unique peptide VV1A and IAT. LC-MS/MS results indicated that they do not significantly affect the CTF83 and CTF99 cleavage line either. Second, six mutations (I143T, H163P, S170F, Q223R, M233V, and G384A) change the ratio of $\alpha$-42/40 by decreasing the level of $\alpha$-40 and increasing the level of $\alpha$-42, respectively. Meanwhile, the cleavage of $\alpha$-42 to $\alpha$-38 and of $\alpha$-43 to $\alpha$-40 were both decreased. Such results indicate that those mutations affect the $\alpha$-42/40 ratio through both the $\alpha$-49-40 line and the $\alpha$-48-42 line. Third, one mutation (L166P) affected the ratio of $\alpha$-42/40 by decreasing the level of $\alpha$-40 as a result of the decreased specific cleavage of $\alpha$-43 to $\alpha$-40, with no effect on $\alpha$-42. This outcome indicates that L166P affects the $\alpha$-42/40 ratio mainly through the $\alpha$-49-40 line. Fourth, six mutations (I143V, M146V, G217A, E280A, L381V, and L392V) affected the ratio of $\alpha$-42/40 by increasing the level of $\alpha$-42, via specifically decreasing the cleavage of $\alpha$-42 to $\alpha$-38, with no effect on $\alpha$-40. This outcome suggests that those mutations affect the $\alpha$-42/40 ratio mainly through the $\alpha$-48–$\alpha$-40 line. To summarize, except for the negative control (D385A), which showed no effect on the $\alpha$-42/40 and the process of $\beta$-CTF cleavage, most of PS1 mutations could change the $\alpha$-42/40 ratio through different long form $\alpha$-CTF cleavage lines (Figure 7).

Exactly how FAD mutations lead to the AD neuropathogenesis is still a mystery at present. One prevailing hypothesis is that PS mutations in mammalian systems cause the increase of the $\gamma$-secretase activity and enhance $\alpha$-42 production (Shioi et al., 2007). Conversely, some new studies suggest that some mutations in FAD PS1 mutations (i.e., V82L, C263R et al.) not only would not increase production of $\alpha$-42, but also lead to a loss of its essential functions. Many studies showed that FAD PS1 mutations would increase the ratio of $\alpha$-42/$\alpha$-40. However, previous studies primarily focus on, the lowered production of $\alpha$-40, rather than the increased production of $\alpha$-42 (Shen and Kelleher, 2007). Our data seems to be in agreeing with the previous hypotheses. Here, we show that L166p impacts the $\alpha$-42/$\alpha$-40 ratio by decreasing the level of $\alpha$-40, rather than increasing the level of $\alpha$-42 corresponds with previous work. Three PS1 mutations (L133P, G183V, and insR352) were found to cause a lack of amyloid pathology (Raux et al., 2000; Amtul et al., 2002; Dermaut et al., 2004) and an absence of $\alpha$-amyloid accumulation. Such mutations are believed to be associated with Frontotemporal Dementia (FTD) more than with FAD, despite the fact they can be found in both FAD and FTD patients. The data we collected leads us to believe that most FAD PS1 mutations lead to amyloid pathogenesis. This outcome maybe due to FAD PS1 mutations function in regulating the cleavage of $\alpha$-42–$\alpha$-38 and $\alpha$-43–$\alpha$-40.

Interestingly, our results indicated that PS1 mutations have different effects on the $\beta$-CTF and APP processing of $\alpha$-amyloid generation. It is known that APP can be cleaved by $\beta$-secretase and $\alpha$-secretase, generating $\beta$-CTF and $\alpha$-CTF. Subsequently, $\alpha$-CTF and $\beta$-CTF may both be cleaved by $\gamma$-secretase. Additionally, $\alpha$-CTF may remain the same peptide through the processing of $\gamma$-secretase cleavage. Here, we detected tri-peptides and tetra-peptides in the HEK293 cell linings co-transfected with the PS1 mutation and CTF83. We found that $\alpha$-CTF is also processed by a series of continuous cleavages that produce the same tri-peptides and tetra-peptides as that of $\beta$-CTF. Moreover, the PS1 mutation could alter the cleavage process of $\alpha$-CTF as well. Some mutations have different effects on the processing of $\alpha$-CTF and $\beta$-CTF cleavages, suggesting that changes in the PS1 structure may decrease a $\beta$-CTF cleavage with no effect on $\alpha$-CTF.

CONCLUSION

Most mutations in PS1 accelerate the amyloid formation by affecting the $\alpha$-amyloid generation process that results in a change of $\alpha$-42/40 in FAD causing dementia.

AUTHOR CONTRIBUTIONS

NL and YQ contributed to the cell culture and sample preparation. ZR contributed to the data analysis. KL contributed to the sample detection by LC-MS/MS. DR and YD contributed to the experimental design and discussion. NL and HQ contributed to study design and manuscript preparation.

ACKNOWLEDGMENTS

This study was funded by National Natural Science Foundation of China (No. 81171206) and partially supported by the ministry of Science and Technology, China (No. 2013YQ03059514) and a grant from the Key Laboratory for Neurodegenerative Disease of Ministry of Education (No. 2015SJBX05, 2015SJZS01).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fnagi.2016.00051
REFERENCES

Adlard, P. A., Cherny, R. A., Finkelstein, D. L., Gautier, E., Robb, E., Cortes, M., et al. (2008). Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased intestinal Abeta. *Neurobiol. Dis.* 30, 1–8. doi: 10.1016/j.nbd.2008.06.018

Ament, Z., Lewis, P. A., Piper, S., Crook, R., Baker, M., Findlay, K., et al. (2002). A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch. *Neurobiol. Dis.* 9, 269–273. doi: 10.1006/ndis.2001.0473

Barnwell, E., Padmaraju, V., Baranello, R., Pacheco-Quinto, J., Crosson, C., Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., et al. (2002). A novel PSEN1 H163P mutation in a patient with early-onset Alzheimer's disease: clinical, neuroimaging, and neuropathological findings. *Neurosci. Lett.* 330, 109–114. doi: 10.1016/S0304-3940(02)02254-6

Kim, J., Bagnywnsky, E., Chang, Y. H., Choe, G., Choi, B. O., An, S. S., et al. (2012). A novel PSEN1 H163P mutation in a patient with early-onset Alzheimer's disease: clinical, neuroimaging, and neuropathological findings. *Neurosci. Lett.* 530, 109–114. doi: 10.1016/j.neulet.2012.09.040

Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., et al. (2007). Abeta40 inhibits amyloid deposition in vivo. *J. Neurosci.* 27, 627–633. doi: 10.1523/NNEURSCI.4849-06.2007

Kim, S. H., Leem, J. Y., Lah, J. J., Slunt, H. H., Levey, A. I., Thinakaran, G., et al. (2001). Multiple effects of aspartate mutant presenilin 1 on the processing and trafficking of amyloid precursor protein. *J. Biol. Chem.* 276, 43343–43350. doi: 10.1074/jbc.M108245200

Kretner, B., Fukushima, A., Gutsiedied, A., Page, R. M., Luebbers, T., Galley, G., et al. (2011). Attenuated Abeta42 responses to low potency gamma-secretase modulators can be overcome for many pathogenic presenilin mutants by second-generation compounds. *J. Biol. Chem.* 286, 15240–15251. doi: 10.1074/jbc.M110.213587

Lesse, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., et al. (2006). A specific amyloid-beta proteinase in the brain impairs memory. *Nature* 440, 352–357. doi: 10.1038/nature04533

Li, Y., Zhou, W., Tong, Y., He, G., and Song, W. (2006). Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription. *FASEB J.* 20, 285–292. doi: 10.1096/fj.05-4986com

Okochi, M., Tagami, S., Yanagida, K., Takami, M., Kodama, S. T., Mori, K., et al. (2013). Gamma-secretase modulators and presenilin 1 mutants act differently on presenilin/gamma-secretase function to cleave Abeta42 and Abeta43. *Cell Rep.* 3, 42–51. doi: 10.1016/j.celrep.2011.11.028

Olsson, F., Schmidt, S., Althoff, V., Munter, L. M., Jin, S., Rosqvist, S., et al. (2014). Characterization of intermediate steps in amyloid beta (Abeta) production under near-native conditions. *J. Biol. Chem.* 289, 1540–1550. doi: 10.1074/jbc.M113.498246

Piccini, A., Zanusso, G., Borghi, R., Noviello, C., Monaco, S., Russo, R., et al. (2007). Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype. *Arch. Neurol.* 64, 738–745. doi: 10.1001/archneur.64.5.738

Qing, H., Zhou, W., Christensen, M. A., Sun, X., Tong, Y., and Song, W. (2004). Degradation of BACE by the ubiquitin-proteasome pathway. *FASEB J.* 18, 1571–1573. doi: 10.1096/fj.04-19944u

Qi, Takahara, Y., Morishima-Kawashima, M., Tanimura, Y., Dolios, G., Hirotani, N., Horikoshi, Y., et al. (2005). Longer forms of amyloid protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. *J. Neurosci.* 25, 436–445. doi: 10.1523/NNEURSCI.1575-04.2005

Raux, G., Gantiier, R., Thomas-Anterion, C., Boulliat, J., Verpillat, P., Hannequin, D., et al. (2000). Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation. *Neurology* 55, 1393–1398. doi: 10.1212/WNL.55.10.1577

Schagger, H. (2006). Tricine-SDS-PAGE. *Nat. Protoc.* 1, 16–22. doi: 10.1038/nprot.2006.4

Shankar, M. G., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, L., et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat. Med.* 14, 837–842. doi: 10.1038/nm1782

Shen, J., and Kelleher, R. J. III. (2007). The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. *Proc. Natl. Acad. Sci. U.S.A.* 104, 403–409. doi: 10.1073/pnas.0608332104

Shiomi, J., Georgakopoulous, A., Mehta, P., Kouchi, Z., Litterst, C. M., Baki, L., et al. (2007). FAD mutants unable to increase neurotoxic: Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta. *J. Neurochem.* 101, 674–681. doi: 10.1111/j.1471-4159.2006.04391.x

Spasic, D., Tolia, A., Dillen, K., Baert, V., De Strooper, B., Vrijens, S., et al. (2006). Presenilin-1 maintains a nine-transmembrane topology.
throughout the secretory pathway. *J. Biol. Chem.* 281, 26569–26577. doi: 10.1074/jbc.M600592200

Sun, X., Chen, W. D., and Wang, Y. D. (2015). beta-Amyloid: the key peptide in the pathogenesis of Alzheimer's disease. *Front. Pharmacol.* 6:221. doi: 10.3389/fphar.2015.00221

Takami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S., et al. (2009). gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. *J. Neurosci.* 29, 13042–13052. doi: 10.1523/JNEUROSCI.2362-09.2009

Thinakaran, G., and Koo, E. H. (2008). Amyloid precursor protein trafficking, processing, and function. *J. Biol. Chem.* 283, 29615–29619. doi: 10.1074/jbc.R800019200

Uttner, I., Kirchheiner, J., Tumani, H., Mottaghy, F. M., Lebedeva, E., Ozer, E., et al. (2010). A novel presenilin1 mutation (Q223R) associated with early onset Alzheimer's disease, dysarthria and spastic paraparesis and decreased Abeta levels in CSF. *Eur. J. Neurol.* 17, 631–633. doi: 10.1111/j.1468-1331.2009.02810.x

Wanngren, J., Lara, P., Ojemalm, K., Maioli, N., Chen, L., et al. (2014). Changed membrane integration and catalytic site conformation are two mechanisms behind the increased Abeta42/Abeta40 ratio by presenilin 1 familial Alzheimer-linked mutations. *FEBS Open. Biol.* 4, 393–406. doi: 10.1016/j.jfeb.2014.04.006

Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., and Selkoe, D. J. (1999). Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. *Nature* 398, 513–517. doi: 10.1038/19077

Yu, G., Nishimura, M., Arawaka, S., Levitan, D., Zhang, L., Tandon, A., et al. (2000). Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. *Nature* 407, 48–54. doi: 10.1038/35024009

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Li, Liu, Qiu, Ren, Dai, Deng and Qing. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.